What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Type 2 diabetes mellitus, overweight, or obesity (n=59352). Intervention: Semaglutide and Tirzepatide vs. Placebo or active comparators. Primary outcome: Major adverse cardiovascular events (MACE) (RR 0.71, 95% CI 0.60-0.84, p=<0.001).

What does this research mean for the field?

Semaglutide significantly reduces the risk of major adverse cardiovascular events (RR 0.71) in adults with type 2 diabetes or obesity, whereas the reduction with tirzepatide does not reach statistical significance (RR 0.79). Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 19, 2026Diabetology & Metabolic SyndromeOpen Access

Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis

Q: What are the key findings of this study?

Semaglutide significantly reduced the risk of major adverse cardiovascular events (RR 0.71), whereas the reduction with tirzepatide did not reach statistical significance (RR 0.79).

Q: What does this research mean for the field?

Semaglutide significantly reduces the risk of major adverse cardiovascular events (RR 0.71) in adults with type 2 diabetes or obesity, whereas the reduction with tirzepatide does not reach statistical significance (RR 0.79). Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To systematically evaluate cardiovascular outcomes associated with semaglutide and tirzepatide in adults with type 2 diabetes mellitus, overweight, or obesity.

View Full Paper

Ask AI

Bookmark

Key result

Semaglutide cuts MACE risk ~29% while tirzepatide shows no significant benefit.

RR 0.71
95% CI 0.60-0.84
P<0.001
n=59,352

Why the study?

The study was conducted to systematically evaluate cardiovascular outcomes associated with semaglutide and tirzepatide in adults with type 2 diabetes mellitus, overweight, or obesity.

Do semaglutide and tirzepatide reduce major adverse cardiovascular events in adults with type 2 diabetes mellitus, overweight or obesity?

Population

59,352 adults with T2DM, overweight or obesity across 47 RCTs

Comparison

Semaglutide and tirzepatide vs control

Design

Systematic review and meta-analysis of randomized controlled trials

Authors

ZXZhou Xiao-yuShenyang Pharmaceutical University QWQi WuSouthwest Medical University HLHao-lan LuSouthwest Medical University

Discussion

Member takes

Implication

Semaglutide may lower MACE risk in T2DM or obesity; confirms benefit while leaving tirzepatide evidence inconclusive.

Key Points

To systematically evaluate cardiovascular outcomes associated with semaglutide and tirzepatide in adults with type 2 diabetes mellitus, overweight, or obesity.
Searched PubMed, Embase, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov through November 02, 2024 (PROSPERO CRD420251008819).
Included 47 parallel-group randomized controlled trials involving 59,352 participants with intervention durations ranging from 26 to 104 weeks.
Semaglutide reduced the risk of major adverse cardiovascular events (RR, 0.71; 95% CI [0.60–0.84]; p < 0.001), cardiovascular death (RR, 0.81; 95% CI [0.72–0.93]; p = 0.002), myocardial infarction (RR, 0.70; 95% CI [0.61–0.80]; p < 0.001), and heart failure (RR, 0.60; 95% CI [0.41–0.87]; p = 0.007), but not stroke (RR, 0.86; 95% CI [0.73-1.00]; p = 0.056).
Tirzepatide was associated with lower risk of myocardial infarction (RR, 0.63; 95% CI [0.40-1.00]; p = 0.049), but reductions in major adverse cardiovascular events were not statistically significant (RR, 0.79; 95% CI [0.54–1.17]; p = 0.245), with non-significant associations for cardiovascular death, heart failure, and stroke.

Study Design

Type

Meta-Analysis (n=59,352)

Multicenter

Yes

Structured PICO

Do semaglutide and tirzepatide reduce major adverse cardiovascular events in adults with type 2 diabetes mellitus, overweight or obesity?

Population

59,352 adults with type 2 diabetes, overweight, or obesity from 47 randomized controlled trials followed for 26 to over 104 weeks.

Intervention

Semaglutide and tirzepatide

Comparator

Control

Outcome

Major adverse cardiovascular events (MACE)composite

Main Result

Relative Risk: 0.71 (95% CI 0.6–0.84)

p-value: p=<0.001

Semaglutide demonstrates a consistent reduction in major adverse cardiovascular events in adults with T2DM or obesity, whereas evidence for tirzepatide remains limited and uncertain.

Limitations

Most available data were derived from separate drug-versus-control trials, limiting definitive comparative evidence between the two agents.
Non-significant findings for tirzepatide may reflect limited event numbers and imprecision rather than definitive evidence of no effect.
Potential bias due to deviations from intended interventions, primarily in open-label or less conventional trial designs.
Most available data were derived from separate drug-versus-control trials, preventing definitive comparative evidence favoring one agent over the other

Cite This Study

Xiao-yu et al. (2026) conducted a meta-analysis in Type 2 diabetes mellitus, overweight, or obesity (n=59,352). Semaglutide and Tirzepatide vs. Placebo or active comparators was evaluated on Major adverse cardiovascular events (MACE) (RR 0.71, 95% CI 0.60-0.84, p=<0.001). Semaglutide significantly reduced the risk of major adverse cardiovascular events (RR 0.71), whereas the reduction with tirzepatide did not reach statistical significance (RR 0.79).

synapsesocial.com/papers/6a35982fdd3be7785e70ed32 https://doi.org/10.1186/s13098-026-02163-7

View Full Paper

Ask AI

Bookmark